Mechanism of Action: Radioligand Activity
✉ Email this page to a colleague
Drugs with Mechanism of Action: Radioligand Activity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
